

1 **Supplementary Materials**

2

3 **Label-free optical metabolic imaging of adipose tissues for prediabetes diagnosis**

4

5 Liping Chen<sup>1, 2</sup>, Guihui Qin<sup>1, 2</sup>, Yuhong Liu<sup>3</sup>, Moxin Li<sup>1, 2</sup>, Yue Li<sup>1, 2</sup>, Lun-Zhang Guo<sup>4</sup>,  
6 Lidong Du<sup>1, 2</sup>, Weiming Zheng<sup>5</sup>, Pei-Chun Wu<sup>1, 6</sup>, Yueh-Hsun Chuang<sup>7</sup>, Xiaoyan Wang<sup>1,</sup>  
7 <sup>2\*</sup>, Tzung-Dau Wang<sup>8\*</sup>, Ja-An Annie Ho<sup>6\*</sup>, Tzu-Ming Liu<sup>1, 2\*</sup>

8

9 <sup>1</sup>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macao SAR,  
10 China.

11 <sup>2</sup>MOE Frontiers Science Center for Precision Oncology, University of Macau, Macao SAR, China.

12 <sup>3</sup>School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006,  
13 China.

14 <sup>4</sup>Institute of Biomedical Engineering, National Taiwan University, Taipei 10617, Taiwan.

15 <sup>5</sup>Translational Medicine R&D Center, Zhuhai UM Science and Technology Research Institute, Zhuhai,  
16 China.

17 <sup>6</sup>Department of Biochemical Science & Technology, National Taiwan University, Taipei 10617, Taiwan.

18 <sup>7</sup>Department of Anesthesiology, National Taiwan University Hospital and College of Medicine, Taipei  
19 10002, Taiwan.

20 <sup>8</sup>Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan  
21 University Hospital and College of Medicine, Taipei 10002, Taiwan.

22

23 \*Corresponding author. Tzu-Ming Liu, tmliu@um.edu.mo; Ja-An Annie Ho, jaho@ntu.edu.tw; Tzung-  
24 Dau Wang, tdwang@ntu.edu.tw; Xiaoyan Wang, xiaoyanwang85@yahoo.com. Address: Faculty of  
25 Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macao SAR, China. TEL:  
26 +853-8822-4693.

27

28

29

30

31

32

|    |   |    |
|----|---|----|
| 33 | <b>Table of contents</b>  |    |
| 34 | Supplementary Text .....  | 3  |
| 35 | Figure S1 .....   | 7  |
| 36 | Figure S2.....  | 9  |
| 37 | Figure S3.....  | 11 |
| 38 | Figure S4.....  | 12 |
| 39 | Figure S5.....  | 13 |
| 40 | Figure S6.....  | 15 |
| 41 | Figure S7.....  | 16 |
| 42 | Figure S8.....  | 18 |
| 43 | Figure S9.....  | 18 |
| 44 | Figure S10.....   | 20 |
| 45 | Figure S11 .....  | 20 |
| 46 | Table S1. ROC analysis for adipocytes (1 month of feeding) .....                          | 22 |
| 47 | Table S2. ROC analysis for macrophages (4 months of feeding).....                         | 22 |
| 48 | Table S3. ROC analysis for adipocytes (4 months of feeding).....                          | 23 |
| 49 | Table S4. Mean and standard deviation (SD) of all optical readouts in control adipose     |    |
| 50 | tissues and the z-scores of all groups represented in the heatmaps .....                  | 23 |
| 51 | Table S5. ROC analysis of PCA differentiation accuracy .....                              | 25 |
| 52 | Table S6. ROC analysis on optical readouts of adipocytes for differentiating control from |    |
| 53 | HFD and HFHSD-fed mice (feeding for 2 months) .....                                       | 25 |
| 54 | Supplementary methods.....  | 27 |
| 55 | Forest plot of Odds Ratios: Screening the association between optical matrices and        |    |
| 56 | diabetes .....  | 31 |
| 57 | References.....   | 34 |
| 58 |   |    |
| 59 |   |    |
| 60 |   |    |
| 61 |   |    |
| 62 |   |    |
| 63 |   |    |

64 **Supplementary Text**

65 **Validation that GFP-positive cells in adipose tissue of C57BL/6J-c2J-LysM-eGFP**  
66 **mice are macrophages.**

67 An immunostaining assay was conducted to verify if GFP-positive cells in the  
68 epididymal fat of C57BL/6J-c2J-LysM-eGFP mice are macrophages. Fixed adipose tissue  
69 was stained with Alexa Fluor 647 anti-mouse F4/80 antibody. Under the excitation of 960  
70 nm and 1200 nm respectively, GFP and Alexa Fluor 647 were visualized in adipose tissue  
71 (**Figure S1A**). GFP-positive cells can be labeled with Alexa Fluor 647 anti-mouse F4/80  
72 antibody. GFP and Alexa Fluor 647 showed good co-localization, with a PCC value of  $0.58$   
73  $\pm 0.042$ , an MCC-M1 value of 0.99, and an MCC-M2 value of 1. It suggests that GFP-  
74 positive cells express the F4/80 marker (**Figure S1B**).

75

76 ***In vitro* validation of lipofuscin-like fluorescence as a label-free marker for**  
77 **macrophages.**

78 Immunofluorescent staining of CD86, CD206, and CD163 with flow cytometric  
79 analysis confirmed that bone marrow-derived macrophages (BMDMs) were successfully  
80 polarized (**Figure S1C**). The characteristic fluorescence of lipofuscin-like pigments was  
81 almost absent in other cell lines, such as 3T3-L1 cells (**Figure S1D**). To further confirm  
82 that red autofluorescence is derived from lipofuscin-like pigments, co-localization analysis  
83 of lysosomal and lipofuscin-like fluorescence was performed in BMDMs (**Figure S1E**).  
84 Colocalization coefficient values including PCC ( $0.53 \pm 0.048$ ) and MCC (M1 =  $0.93 \pm$   
85  $0.037$ , M2 =  $0.97 \pm 0.011$ ) demonstrated a good correlation and high co-occurrence (**Figure**  
86 **S1F**). It can be determined that the fluorescent substance is a lipofuscin-like pigment  
87 according to the fluorescence emission spectrum (**Figure S1G**).

88

89 **Exploration of prediabetes and diabetes models over time.**

90 Previous studies have shown that in the presence of overnutrition, the metabolism of  
91 adipose tissue could be switched from OXPHOS to glycolysis, and adipose tissue  
92 macrophages are polarized to M1 macrophages. Besides, nutrient excess also affects  
93 macrophage mtDNA release, mtROS production, and mitochondrial dynamics and  
94 promotes obesity-induced inflammation [1-5]. Thus, in the present study, we chose the

95 dietary-induced diabetes model, which has unique advantages in simulating the etiology of  
96 human T2DM, especially the onset characteristics of obese patients with diabetes mellitus.  
97 Two different diets were used to induce diabetes models since pathologic responses may  
98 vary in different dietary components. Long-term exposure to a high-fat diet (HFD) with  
99 60% kcal fat (D12492i, Research Diets Inc., New Brunswick, NJ, USA) causes several  
100 pathologies, including obesity, insulin resistance (IR) [6], inflammation [7], fatty liver [8],  
101 diabetic renal injury, and intestinal barrier dysfunction [9], and neurodegeneration [10].  
102 Prolonged consumption of a high-fat-high-sucrose diet (HFHSD) with 58% kcal fat and  
103 sucrose (D12331i, Research Diets Inc., New Brunswick, NJ, USA) leads to obesity, IR,  
104 and diabetic myocardial damage [11], and fatty liver [12].

105 To find out when IR and diabetes developed in mice, we measured the mice's fasting  
106 blood glucose and insulin levels weekly. We found that the mice body weight of the HFD  
107 and HFHSD groups increased significantly compared with the control group fed with  
108 normal chow (**Figure S2A**). Although HFD- and HFHSD-fed mice exhibited elevated  
109 fasting insulin levels at weeks 5 and 6, respectively (**Figure S2B**), both groups had  
110 significantly higher HOMA-IR index at week 5 than the control group (**Figure 2A**). Mice  
111 fed HFD or HFHSD showed increased HOMA-IR value, suggesting the presence of IR [13,  
112 14]. Prediabetes refers to an intermediate hyperglycemia [15, 16] state in which insulin  
113 resistance (IR) is already present and blood glucose levels are higher than normal but lower  
114 than those in diabetes. In this study, we expected to establish a prediabetes detection  
115 method, that is, the IR stage, so we chose the time around the onset of IR as the detection  
116 time point, the 4<sup>th</sup> week of HFD or HFHSD feeding. Comparing the metabolic profiles of  
117 prediabetes and diabetes is conducive to the establishment of detection technology for  
118 prediabetes, so it is also important to find out the onset of diabetes.

119 Although impaired fasting glucose levels were detected after 8 weeks of feeding on  
120 HFD or HFHSD (**Figure 2B**), these mice displayed clear-cut diabetes with fasting blood  
121 glucose levels of above 13 mmol/L at the 16<sup>th</sup> week, which was compatible with the  
122 previous study [17]. Furthermore, random blood glucose levels were significantly elevated  
123 only after 16 weeks of HFD or HFD feeding (**Figure S2C**). Thus, we set the 16<sup>th</sup> week of  
124 feeding on HFD or HFHSD as the time point for diabetes diagnosis. So, the period from  
125 the presence of IR until the fasting blood glucose level reaches 13 mmol/L is the prediabetic


126 state. That is, mice fed HFD or HFHSD for 4 to 15 weeks are considered prediabetic. From  
127 16 weeks onwards, mice entered the diabetic stage. Besides, we found that IR precedes  
128 hyperglycemia, which is consistent with previous studies [18-20].

129 Anatomical diagrams of mice demonstrated that epididymal fat hypertrophy was  
130 observed in mice fed HFD or HFHSD for either 1 or 4 months (**Figure S2D-E**). Besides,  
131 we performed a 2-NBDG glucose uptake assay to verify that adipose tissue developed  
132 insulin resistance in mice fed HFD or HFHSD for 1 and 4 months. 2-NBDG is a fluorescent  
133 tracer used to monitor glucose uptake by living cells. Measurement of glucose uptake rate  
134 reflects insulin sensitivity [21, 22]. Fluorescence images and signals were acquired to  
135 ensure that 2-NBDG was absorbed by adipose tissue, and the result showed the peak of the  
136 spectrum was at 540 nm, which is the emission wavelength of 2-NBDG (**Figure S2F-G**).  
137 2-NBDG uptake by epididymal fat was significantly reduced in mice fed HFD or HFHSD  
138 (**Figure S2H**), indicating that epididymal fat may have IR.

139 During the establishment of IR and diabetes mice models, in addition to tracking  
140 changes in fasting blood glucose and insulin levels, we also performed RNA-seq analysis  
141 of adipose tissue, looking for evidence at the transcriptomic level of whether the IR and  
142 diabetes mice models were successfully established. Heatmap clustering analysis  
143 manifested that HFD or HFHSD feeding for 1 month and 4 months resulted in the down-  
144 regulation of insulin receptor (*Insr*) and its substrate (*Irs1*) in adipose tissue, suggesting IR  
145 in adipose tissue. In addition, an increase of the adipokine leptin (*Lep*) was observed in the  
146 adipose tissue of mice fed HFD or HFHSD for 1 or 4 months (Supplementary Figure S2i,  
147 j). Up-regulation of leptin is associated with the increased risk of IR and T2DM [23-25].  
148 Adiponectin (*Adipoq*) is another adipokine with the opposite biological function to leptin  
149 in inflammation and IR [26]. Compared with the control group, although the down-  
150 regulation of adiponectin and its receptor (*Adipor2*) was not detected at 1 month of HFD  
151 or HFHSD feeding, the expression of these two genes was down-regulated in both HFD  
152 and HFHSD groups after 4 months of feeding, indicating that long-term feeding of  
153 HF(HS)D causes more severe symptoms of adipose tissue IR than short-term feeding.  
154 Accumulated evidence revealed that mitochondrial dysfunction could be one of the  
155 pathogenic factors of IR and T2DM [27, 28]. Suppression of metabolic genes involved in  
156 mitochondrial biogenesis and glucose/fatty acid metabolism including proliferator

157 peroxisome-activated receptor (PPAR) coactivator-1 $\alpha$ , PGC-1 $\alpha$  (Ppargc1a), the PPARs  
158 members (Ppara, Ppard, and Pparg), and 5'AMP-activated protein kinase (AMPK) (Prkaa1,  
159 Prkaa2, Prkab2) were observed in T2DM subjects [29-31]. In our study, both short- and  
160 long-term exposure to HF(HS)D resulted in the down-regulation of these metabolic genes,  
161 implying mitochondrial dysfunction in adipose tissue. Evidence from RNA-seq supported  
162 the successful construction of IR and diabetes mice models in this study.

163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187



190 **Figure S1. Lipofuscin-like red autofluorescence is specific to adipose tissue macrophages.** (A)  
191 Colocalization of GFP and macrophage marker F4/80 in the visceral fat of C57BL/6J-c2J-LysM-eGFP  
192 mice. GFP excited by 960 nm was presented by green color, and Alexa Fluor 647 anti-mouse F4/80  
193 excited by 1200 nm was presented by red color. Scale bar: 50  $\mu$ m. (B) Colocalization analysis for GFP  
194 and Alexa 647. PCC =  $0.58 \pm 0.04$ , M1 = 0.99, M2 = 1. (n = 3) (C) Flow cytometry assay for different  
195 macrophage phenotypes identification. (D) Representative images of lipofuscin-like red  
196 autofluorescence in 3T3-L1 cells and BMDMs (n = 6). Scale bar: 20  $\mu$ m. (E) Representative images  
197 displaying colocalization of lysotracker green and lipofuscin-like red autofluorescence in BMDMs.  
198 Scale bar: 10  $\mu$ m. (F) Colocalization analysis for lysotracker green and lipofuscin-like red  
199 autofluorescence. PCC =  $0.53 \pm 0.048$ , MCC-M1 =  $0.93 \pm 0.038$ , MCC-M2 =  $0.97 \pm 0.011$ . (G) The  
200 fluorescence emission spectra of lipofuscin-like pigments in macrophages. Data are presented as Mean  
201  $\pm$  SD (n = 3 or 6).

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222


223

224

225



226 **Figure S2**



227

228 **Figure S2. Establishment of Type II Diabetes Mellitus (T2DM)/Pre-T2DM model in mice. (A)**

229 **Weight gain in mice fed HFD or HFHSD for 16 weeks. (B) Fasting insulin levels in mice fed HFD or**

230 HFHSD for 16 weeks. (C) Random blood glucose levels in mice fed HFD or HFHSD for 16 weeks. (D-  
231 E) The representative anatomy diagram of mice (D: 1 month of feeding; E: 4 months of feeding). (F)  
232 The fluorescence emission spectra of 2-NBDG in adipose tissue. (G) Representative fluorescence  
233 images of 2-NBDG glucose uptake in fresh epididymal fat (Top: 1 month of feeding; bottom: 4 months  
234 of feeding). Scale bar: 100  $\mu\text{m}$ . (H) Quantification of relative 2-NBDG fluorescence intensity in adipose  
235 tissue (Left: 1 month of feeding; right: 4 months of feeding). Each group contains 25-30 data points  
236 from 3 biological replicas. Each data point is the average of 10 cells in one field of view. (I-J) Heatmaps  
237 of expression profiles of insulin receptor genes, adipokine genes, and metabolic-related genes in adipose  
238 tissues. Data are expressed as Mean  $\pm$  SD (n = 3). \* $P$  < 0.05, \*\* $P$  < 0.01, and \*\*\* $P$  < 0.001, the HFD  
239 group vs. the control group; # $P$  < 0.05, ## $P$  < 0.01, and ### $P$  < 0.001, the HFHSD group vs. the control  
240 group.

241

242

243

244

245

246

247

248


249

250

251


252

253



256 **Figure S3. Identification of metabolic and inflammatory phenotypes of prediabetic adipose tissue.**  
257 (A) Expression profile of glycolysis-related genes in adipose tissues of normal and prediabetic mice  
258 (HFD or HFHSD fed for 1 month). (B) (left panel) Seahorse analysis of oxygen consumption rate (OCR)  
259 of normal and prediabetic adipose tissues. (right panel) Comparative analysis of basal respiration, ATP  
260 production, and maximum respiration capacity in adipose tissues of healthy and prediabetic mice. (C)  
261 (left panel) Seahorse analysis of extracellular acidification rate (ECAR) of normal and prediabetic  
262 adipose tissues. (right panel) Comparative analysis of glycolysis, glycolytic capacity, and glycolytic  
263 reserve in adipose tissues of normal and prediabetic mice. (D) (upper panel) Hematoxylin and Eosin  
264 (H&E) staining and immunostaining of F4/80, CD68, CD80, iNOS and CD206 in epididymal fat from  
265 normal and prediabetic mice. (lower panel) Quantification of relative expression of F4/80, CD68, CD80,  
266 iNOS, and CD206 in adipose tissue paraffin sections. Data are expressed as Mean  $\pm$  SD (n = 3). \* $P$  <  
267 0.05 and \*\* $P$  < 0.01 relative to the control group.  
268


269 **Figure S4**



270

271 **Figure S4. Optical metrics of adipocytes in diabetic adipose tissues.** (A) Quantification of redox  
 272 ratio in adipocyte cytoplasm of epididymal adipose tissues from mice fed HFD or HFHSD for 4 months.  
 273 Data are presented as Mean  $\pm$  SD. Each group contains 25-30 data points from 8 biological replicas.  
 274 Each data point is the average of 10 cells in one field of view. \*\*\* $P < 0.001$  versus the control group. (B)  
 275 The 2D scatter plot displayed that the two parameters  $a_1$  and  $t_2$  can distinguish the adipocytes of the  
 276 control, HFD, and HFHSD groups, with an original classification accuracy of 91.2% (control versus  
 277 HFD) or 85.5% (control versus HFHSD) and a cross-validation classification accuracy of 91.2%  
 278 (control versus HFD) or 85.5% (control versus HFHSD). Each group contains 25-30 data points from 8  
 279 biological replicas. Each data point is the average of 10 cells in one field of view. (C, D) ROC curves  
 280 and AUC values for optical readouts (redox ratio,  $a_1$ ,  $t_1$ ,  $t_2$ , and  $t_2$ - $a_1$ -redox ratio-integrated parameter)  
 281 of adipocytes, showing their ability to distinguish between (C) control and HFD groups or between (D)  
 282 control and HFHSD groups. Other parameters of ROC and AUC analyses were shown in Table S3.

283 **Figure S5**



284


285 **Figure S5. Histopathological examination of adipose tissues from mice fed for 4 months. (A)**

286 Hematoxylin and Eosin (H&E) staining of epididymal fat in control mice and diabetic mice (HFD and



287 HHFSD groups). The red arrow marks the crown-like structures (CLSs). The bar chart shows the  
 288 number of CLSs. Immunostaining of (B) F4/80, (C) CD68, (D) CD80, (E) iNOS, and (F) CD206 in  
 289 paraffin sections of adipose tissues showing CLSs. Relative expression of F4/80, CD68, CD80, iNOS,  
 290 and CD206 in adipose tissue sections was quantified using Image Pro Plus. Scale bar: 250  $\mu\text{m}$  for large  
 291 images and 50  $\mu\text{m}$  for inset images in (B) and (C), 50  $\mu\text{m}$  in (D), (E), and (F). Data are presented as  
 292 Mean  $\pm$  SD ( $n = 3$ ). \* $P < 0.05$ , \*\* $P < 0.01$ , and \*\*\* $P < 0.001$  versus the control group.  
 293

294 **Figure S6**




295

296 **Figure S6. TPFM and FLIM metabolic imaging of BMDMs.** (A) Representative images of NAD(P)H  
297 and FAD fluorescence intensity in different phenotypes of BMDMs, including M0, M1, and M2. Scale  
298 bar: 20  $\mu\text{m}$ . (B) Quantification of redox ratio of M0, M1, and M2 macrophages. (C) Representative  
299 pseudo-color-coded FLIM  $a_1$  and  $t_2$  images of NAD(P)H of M0, M1, and M2 macrophages. Scale bar:  
300 20  $\mu\text{m}$ . (D) The  $a_1$ - $t_2$  scatter plot manifests a good separation of M1 from M0 (original classification  
301 accuracy: 83.9% cross-validation: 83.9%), and M1 from M2 (original classification accuracy: 87.8%  
302 cross-validation: 87.8%). Quantification of free NAD(P)H fraction  $a_1$  (E) and long lifetime component  
303  $t_2$  (F) in BMDMs. Each group in (B, D, E, F) contains 25-30 data points from 6 biological replicas. Each  
304 data point is the average of 10 cells in one field of view. Data in (B, D, E, F) are presented as Mean  $\pm$   
305 SD. \*\*\* $P < 0.001$  compared with the control group.

306 **Figure S7**





307

308

**Figure S7. Identification of metabolic profile of diabetic adipose tissue.** (A) Heatmap of glycolysis-

309

related genes' expression in adipose tissues of the control and diabetic mice (HFD or HFHSD fed for 4

310

months). (B) (left panel) Oxygen consumption rate (OCR) profile plots of epididymal fat from the

311

control and diabetic mice. (right panel) Quantification of basal respiration, ATP production, and

312

maximum respiration capacity in epididymal fat of the control and diabetic mice. (C) (left panel)

313


Extracellular acidification rate (ECAR) profile plots of adipose tissue from the control and diabetic

314

mice. (right panel) Quantification of glycolysis, glycolytic capacity, and glycolytic reserve in adipose


315 tissues of the control and diabetic mice. Data are shown as Mean  $\pm$  SD (n = 3). \*\**P* < 0.01 relative to the  
316 control group.  
317

318 **Figure S8**



319  
320 **Figure S8. Diet changes improving prediabetes symptoms in mice.** (A) Timeline showing mice fed  
321 HFD or HFHSD for 2 months, followed by normal chow for 1 month. Mice's blood glucose levels were  
322 monitored by using an insulin tolerance test (ITT) (B) and an intraperitoneal glucose tolerance test  
323 (IPGTT) (C) (n = 8). (D) HE staining of adipose tissue (n = 3). (E) Quantification of adipocyte size.  
324 Data are represented as Mean  $\pm$  SD (n = 3 or 8).

325 **Figure S9**



326

327 **Figure S9. TPFM and FLIM metabolic imaging of epididymal fat in prediabetic mice.** (A)

328 Representative images of NAD(P)H, FAD, and lipofuscin-like fluorescence intensity in epididymal fat

329 from mice fed HFD or HFHSD for 2 months. Scale bar: 50  $\mu$ m. The redox ratios of adipocytes (B) and


330 macrophages (C) were quantified. Data were presented as Mean  $\pm$  SD (n = 8). \*\*\*P < 0.001 versus the

331 control group. (D) False-color-coded FLIM  $a_1$  and  $t_2$  images of NAD(P)H in adipose tissues. Scale bar:

332 50  $\mu$ m. The  $a_1$ - $t_2$  scatter plots of (E) adipocytes and (F) macrophages. (G, H) ROC curves and AUC






333 values for optical readouts (redox ratio,  $a_1$ ,  $t_1$ ,  $t_2$ , and  $t_2$ - $a_1$ -redox ratio-integrated parameter) of  
334 adipocytes, showing their ability to distinguish between (G) control and HFD groups or between (H)  
335 control and HFHSD groups. Other parameters of ROC and AUC analysis were shown in **Table S6**.  
336 Each group in (B, C, E, and F) contains 25-30 data points from 8 biological replicas. Each data point is  
337 the average of 10 cells in one field of view.  
338

339 **Figure S10**



340  
341 **Figure S10. NAD(P)+/NAD(P)H content measurement.** (A-B) Relative NAD(P)+/NAD(P)H content  
342 in adipose tissue. Adipose tissue from mice fed for 1 month (A) and 4 months (B) respectively. Data  
343 are represented as Mean  $\pm$  SD (n = 3).  
344

345 **Figure S11**



346  
 347 **Figure S11. No changes in the redox ratio and NAD(P)H lifetime of adipocytes were observed in**  
 348 **mice fed HFD or HFHSD for 2 weeks.** (A) Representative images of NAD(P)H, FAD, and lipofuscin  
 349 fluorescence intensity. Scale bar: 50  $\mu$ m. (B) Quantification of redox ratio in adipocytes. (C)  
 350 Quantification of redox ratio in macrophages. (D) FLIM images of adipose tissues. Scale bar: 50  $\mu$ m.  
 351 (E) The  $a_1$ - $t_2$  scatter plot. Data are represented as mean  $\pm$  SD ( $n = 8$ ). Each group in (B, C, E) contains  
 352 25-30 data points from 8 biological replicas. Each data point is the average of 10 cells in one field of  
 353 view.  
 354

**Table S1. ROC analysis for adipocytes (1 month of feeding)**

| Group                  | Optical index         | ROC curve   |             |      |              |        |
|------------------------|-----------------------|-------------|-------------|------|--------------|--------|
|                        |                       | Sensitivity | Specificity | AUC  | Youden index | Cutoff |
| Control<br>vs<br>HFD   | t <sub>1</sub>        | 60.61%      | 50%         | 0.52 | 0.11         | 477    |
|                        | t <sub>2</sub>        | 93.94%      | 68.42%      | 0.82 | 0.62         | 2802   |
|                        | a <sub>1</sub>        | 93.94%      | 92.11%      | 0.87 | 0.86         | 60.05  |
|                        | Redox ratio           | 90.91%      | 71.05%      | 0.8  | 0.62         | 0.08   |
|                        | Predicted probability | 96.97%      | 100%        | 0.96 | 0.97         | 0.58   |
| Control<br>vs<br>HFHSD | t <sub>1</sub>        | 35.14%      | 76.32%      | 0.5  | 0.11         | 507.6  |
|                        | t <sub>2</sub>        | 75.68%      | 84.21%      | 0.81 | 0.60         | 2729   |
|                        | a <sub>1</sub>        | 78.38%      | 92.11%      | 0.83 | 0.70         | 60     |
|                        | Redox ratio           | 97.30%      | 68.42%      | 0.83 | 0.66         | 0.08   |
|                        | Predicted probability | 89.19%      | 100%        | 0.93 | 0.89         | 0.77   |

356

357

**Table S2. ROC analysis for macrophages (4 months of feeding)**

| Group                | Optical index         | ROC curve   |             |      |              |        |
|----------------------|-----------------------|-------------|-------------|------|--------------|--------|
|                      |                       | Sensitivity | Specificity | AUC  | Youden index | Cutoff |
| Control<br>vs<br>HFD | t <sub>1</sub>        | 88%         | 92.59%      | 0.87 | 0.81         | 451.1  |
|                      | t <sub>2</sub>        | 96%         | 92.59%      | 0.87 | 0.89         | 2345   |
|                      | a <sub>1</sub>        | 56%         | 81.48%      | 0.68 | 0.37         | 75.4   |
|                      | Redox ratio           | 88%         | 62.96%      | 0.77 | 0.51         | 0.44   |
|                      | Lipofuscin intensity  | 84%         | 81.48%      | 0.82 | 0.65         | 1.2    |
|                      | Predicted probability | 100%        | 96.30%      | 0.86 | 0.96         | 0.44   |

|         |                       |        |        |      |      |       |
|---------|-----------------------|--------|--------|------|------|-------|
|         | t <sub>1</sub>        | 85.71% | 100%   | 0.86 | 0.86 | 475   |
|         | t <sub>2</sub>        | 91.43% | 96.30% | 0.87 | 0.88 | 2374  |
| Control | a <sub>1</sub>        | 57.14% | 81.48% | 0.71 | 0.39 | 75.39 |
| vs      | Redox ratio           | 77.14% | 70.37% | 0.76 | 0.48 | 0.43  |
| HFHSD   | Lipofuscin intensity  | 60%    | 88.89% | 0.74 | 0.49 | 1.37  |
|         | Predicted probability | 94.29% | 100%   | 0.88 | 0.94 | 0.63  |

358

359

**Table S3. ROC analysis for adipocytes (4 months of feeding)**

| Group   | Optical index         | ROC curve   |             |      |              | Cutoff |
|---------|-----------------------|-------------|-------------|------|--------------|--------|
|         |                       | Sensitivity | Specificity | AUC  | Youden index |        |
|         | t <sub>1</sub>        | 96.67%      | 20%         | 0.55 | 0.17         | 609.9  |
| Control | t <sub>2</sub>        | 96.67%      | 86.67%      | 0.86 | 0.83         | 2778   |
| vs      | a <sub>1</sub>        | 100%        | 56.67%      | 0.79 | 0.57         | 60.01  |
| HFHD    | Redox ratio           | 76.67%      | 83.33%      | 0.81 | 0.6          | 0.06   |
|         | Predicted probability | 100%        | 96.67%      | 0.88 | 0.97         | 0.47   |
|         | t <sub>1</sub>        | 50%         | 76.67%      | 0.65 | 0.27         | 488.8  |
| Control | t <sub>2</sub>        | 86.67%      | 83.33%      | 0.84 | 0.7          | 2812   |
| vs      | a <sub>1</sub>        | 96.67%      | 56.67%      | 0.73 | 0.53         | 59.7   |
| HFHSD   | Redox ratio           | 83.33%      | 93.33%      | 0.83 | 0.77         | 0.056  |
|         | Predicted probability | 100%        | 90%         | 0.87 | 0.9          | 0.30   |

360

**Table S4. Mean and standard deviation (SD) of all optical readouts in control adipose tissues and the z-scores of all groups represented in the heatmaps**

361

362

363

**Statistics of optical readouts in the control group**

364

| Optical readouts                            | Mean  | SD    |
|---|-------|-------|
| OR1: Adipocyte_redox_ratio                  | 0.090 | 0.022 |
| OR2: Adipocyte_NAD(P)H_a1 (%)               | 55.95 | 3.94  |
| OR3: Adipocyte_NAD(P)H_t1 (ps)              | 470   | 43    |
| OR4: Adipocyte_NAD(P)H_t2 (ps)              | 2827  | 120   |
| OR5: Macrophage_redox_ratio                 | 0.429 | 0.071 |
| OR6: Macrophage_NAD(P)H_a1 (%)              | 71.51 | 3.95  |
| OR7: Macrophage_NAD(P)H_t1 (ps)             | 470   | 60    |
| OR8: Macrophage_NAD(P)H_t2 (ps)             | 2510  | 151   |
| OR9: Macrophage_lipofuscin_FL (Counts/cell) | 10386 | 3864  |

365

366

367

368

**Z-scores of all groups**

| Optical readouts         | Control |       | Prediabetes |       | Diabetes |       |
|--------------------------|---------|-------|-------------|-------|----------|-------|
|                          | HFD     | HFHSD | HFD         | HFHSD | HFD      | HFHSD |
| Adipocyte_redox_ratio    | 0.00    | 0.00  | -1.16       | -1.48 | -1.71    | -1.89 |
| Adipocyte_NAD(P)H_a1     | 0.00    | 0.00  | 2.73        | 2.14  | 2.90     | 2.27  |
| Adipocyte_NAD(P)H_t1     | 0.00    | 0.00  | 0.15        | 0.03  | -0.03    | -0.65 |
| Adipocyte_NAD(P)H_t2     | 0.00    | 0.00  | -1.62       | -1.35 | -1.75    | -1.62 |
| Macrophage_redox_ratio   | 0.00    | 0.00  | -0.05       | -0.04 | -1.21    | -1.11 |
| Macrophage_NAD(P)H_a1    | 0.00    | 0.00  | 0.20        | -0.04 | 0.95     | 1.26  |
| Macrophage_NAD(P)H_t1    | 0.00    | 0.00  | -0.20       | 0.05  | 0.44     | 0.56  |
| Macrophage_NAD(P)H_t2    | 0.00    | 0.00  | -0.52       | -0.13 | 2.51     | 2.73  |
| Macrophage_lipofuscin_FL | 0.00    | 1.00  | 0.00        | 1.05  | 2.83     | 1.94  |

369

370



**Table S5. ROC analysis of PCA differentiation accuracy**

|                          | Group                   | ROC curve   |             |      |              |        |
|--------------------------|-------------------------|-------------|-------------|------|--------------|--------|
|                          |                         | Sensitivity | Specificity | AUC  | Youden index | Cutoff |
| <b>HFD-induced model</b> | Prediabetes vs Diabetes | 100%        | 93.94%      | 0.99 | 0.94         | 0.31   |
|                          | Control vs Prediabetes  | 96.97%      | 85.71%      | 0.85 | 0.83         | 0.40   |
|                          | Control vs Diabetes     | 100%        | 97.14%      | 0.94 | 0.97         | 0.31   |
|                          | Prediabetes vs Diabetes | 83.33%      | 100%        | 0.87 | 1            | 0.71   |
|                          | Control vs Prediabetes  | 37.84%      | 97.14%      | 0.85 | 0.97         | 0.84   |
|                          | Control vs Diabetes     | 73.33%      | 100%        | 0.88 | 1            | 0.98   |

373 **Table S6. ROC analysis on optical readouts of adipocytes for differentiating control**  
374 **from HFD and HFHSD-fed mice (feeding for 2 months)**

|                        |                       | <b>ROC curve</b> |             |      |              |        |
|------------------------|-----------------------|------------------|-------------|------|--------------|--------|
| Group                  | Optical index         | Sensitivity      | Specificity | AUC  | Youden index | Cutoff |
| Control<br>vs<br>HFD   | t <sub>1</sub>        | 68.97%           | 50%         | 0.55 | 0.19         | 559.6  |
|                        | t <sub>2</sub>        | 82.76%           | 92.86%      | 0.84 | 0.76         | 2782   |
|                        | a <sub>1</sub>        | 93.10%           | 60.71%      | 0.74 | 0.54         | 53.61  |
|                        | Redox ratio           | 93.10%           | 89.29%      | 0.85 | 0.82         | 0.057  |
|                        | Predicted probability | 96.55%           | 92.86%      | 0.87 | 0.89         | 0.4    |
| Control<br>vs<br>HFHSD | t <sub>1</sub>        | 40%              | 82.14%      | 0.55 | 0.22         | 471.3  |
|                        | t <sub>2</sub>        | 70%              | 92.86%      | 0.78 | 0.63         | 2781   |
|                        | a <sub>1</sub>        | 86.67%           | 67.86%      | 0.76 | 0.55         | 55.36  |
|                        | Redox ratio           | 83.33%           | 89.29%      | 0.82 | 0.73         | 0.057  |
|                        | Predicted probability | 93.33%           | 89.29%      | 0.86 | 0.83         | 0.43   |


375

376

377 **Supplementary methods**

378 **Procedures for quantifying cellular redox ratio and NAD(P)H lifetime**

**Calculation of macrophage redox ratio**



379


380 1) Locate macrophages based on lipofuscin-like red autofluorescence, and use the  
381 freehand selections tool in Image J to circle the cells with red fluorescence.

382 2) Apply these ROIs to NAD(P)H and FAD fluorescence images, respectively, and  
383 measure the NAD(P)H and FAD intensities of each ROI.

384 3) Calculate the redox ratio of each cell based on the formula of  $I_{FAD} / [I_{NAD(P)H} + I_{FAD}]$ ,  
385 and analyze at least 30 cells' redox ratio.

386

## Calculation of adipocyte redox ratio




387

388 Adipocyte cytoplasm can be visualized in both fluorescence channels, whereas lipids  
389 have little detectable signal in the FAD channel [32]. So, the lipids area and macrophage  
390 region was excluded when calculating the redox ratio. The steps to analyze the redox ratio  
391 of adipocytes are as follows:

- 392 1) Circle the adipocyte cytoplasm on the NAD(P)H fluorescence image using the freehand  
393 selections tool in Image J.
- 394 2) Apply these ROIs to the FAD fluorescence image and measure the NAD(P)H and FAD  
395 intensities of each ROI.
- 396 3) Calculate the redox ratio of each cell based on the formula of  $I_{FAD} / [I_{NAD(P)H} + I_{FAD}]$ ,  
397 and analyze at least 30 cells' redox ratio.

398

## Analysis of macrophage NAD(P)H lifetime



399

400 1) Use an IRF convoluted two-component model  $f(t) = \text{IRF} \otimes (a_1 e^{-t/t_1} + a_2 e^{-t/t_2})$  to fit  
 401 the decay traces.

402 2) Locate macrophages based on lipofuscin fluorescence image.

403 3) Circle macrophages on the NAD(P)H fluorescence lifetime image using the "Define  
 404 mask" tool in SPCImage software.


405 4) Export the optical metrics, including  $a_1$ ,  $t_1$ ,  $a_2$ ,  $t_2$ , and  $t_m$ , and analyze at least 30 cells.

406

407

408

### Analysis of adipocyte NAD(P)H lifetime




409

- 410 1) Use an IRF convoluted two-component model  $f(t) = IRF \otimes (a_1e^{-t/t_1} + a_2e^{-t/t_2})$  to fit
- 411 the decay traces.
- 412 2) Circle the adipocyte cytoplasm on the NAD(P)H fluorescence lifetime image using the
- 413 “Define mask” tool in SPCimage software.
- 414 3) Export the optical metrics, including  $a_1$ ,  $t_1$ ,  $a_2$ ,  $t_2$ , and  $t_m$ , and collect at least 30 cells'
- 415 NAD(P)H lifetime.

416

### 417 Procedures for measuring adipocyte size


#### Measurement of adipocyte size



418


- 419 1-3) Make sure that the pixel resolution of the image agrees with the scale bar.
- 420 4) Manually circle the adipocyte using the freehand selections tool in Image J.
- 421 5) Measure the ROI and obtain the area of adipocytes.

422 **Forest plot of Odds Ratios: Screening the association between optical matrices and**  
 423 **diabetes**



424  
 425 Forest plot showing the association between adipocytes' optical metrics and prediabetes (HFD-induced  
 426 model, 1 month of feeding).


427



428  
 429 Forest plot showing the association between adipocytes' optical metrics and prediabetes (HFHSD-  
 430 induced model, 1 month of feeding).

431

HFD-induced prediabetes model (2-month feeding)




432

433 Forest plot showing the association between adipocytes' optical metrics and prediabetes (HFD-induced  
434 model, 2 months of feeding).

435

HFHSD-induced prediabetes model (2-month feeding)




436

437 Forest plot showing the association between adipocytes' optical metrics and prediabetes (HFHSD-  
438 induced model, 2 months of feeding).

439



HFD-induced diabetes model (4-month feeding)




440

441 Forest plot showing the association between adipocytes' optical metrics and diabetes (HFD-induced  
442 model, 4 months of feeding).

443

HFHSD-induced diabetes model (4-month feeding)




444

445 Forest plot showing the association between adipocytes' optical metrics and diabetes (HFHSD-  
446 induced model, 4 months of feeding).

447

HFD-induced diabetes model (4-month feeding)




448

449 Forest plot showing the association between macrophages' optical metrics and diabetes (HFD-induced  
450 model, 4 months of feeding).

451

HFHSD-induced diabetes model (4-month feeding)



452

453 Forest plot showing the association between macrophages' optical metrics and diabetes (HFHSD-  
454 induced model, 4 months of feeding).

455

456 **References**

- 457 1. Coats BR, Schoenfelt KQ, Barbosa-Lorenzi VC, Peris E, Cui C, Hoffman A, et al.  
458 Metabolically activated adipose tissue macrophages perform detrimental and beneficial functions during  
459 diet-induced obesity. Cell Rep. 2017; 20: 3149-61.
- 460 2. Zhang P, Li T, Wu X, Nice EC, Huang C, Zhang Y. Oxidative stress and diabetes: antioxidative  
461 strategies. Front Med. 2020; 14: 583-600.

- 462 3. Khan MSH, Hegde V. Obesity and diabetes mediated chronic inflammation: a potential  
463 biomarker in alzheimer's disease. *J Pers Med.* 2020; 10.
- 464 4. Bournat JC, Brown CW. Mitochondrial dysfunction in obesity. *Curr Opin Endocrinol Diabetes*  
465 *Obes.* 2010; 17: 446-52.
- 466 5. Catrysse L, van Loo G. Adipose tissue macrophages and their polarization in health and obesity.  
467 *Cell Immunol.* 2018; 330: 114-9.
- 468 6. Barbier-Torres L, Fortner KA, Iruzubieta P, Delgado TC, Giddings E, Chen Y, et al. Silencing  
469 hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty  
470 acid oxidation. *Nat Commun.* 2020; 11: 3360.
- 471 7. Bapat SP, Whitty C, Mowery CT, Liang Y, Yoo A, Jiang Z, et al. Obesity alters pathology and  
472 treatment response in inflammatory disease. *Nature.* 2022; 604: 337-42.
- 473 8. Huang J, Jia Y, Fu T, Viswakarma N, Bai L, Rao MS, et al. Sustained activation of PPAR $\alpha$  by  
474 endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice. *FASEB*  
475 *J.* 2012; 26: 628-38.
- 476 9. Hua Q, Han Y, Zhao H, Zhang H, Yan B, Pei S, et al. Punicalagin alleviates renal injury via  
477 the gut-kidney axis in high-fat diet-induced diabetic mice. *Food Funct.* 2022; 13: 867-79.
- 478 10. Bao J, Liang Z, Gong X, Yu J, Xiao Y, Liu W, et al. High fat diet mediates amyloid- $\beta$  cleaving  
479 enzyme 1 phosphorylation and SUMOylation, enhancing cognitive impairment in APP/PS1 Mice. *J*  
480 *Alzheimers Dis.* 2022; 85: 863-76.
- 481 11. Brahma MK, Ha CM, Pepin ME, Mia S, Sun Z, Chatham JC, et al. Increased glucose  
482 availability attenuates myocardial ketone body utilization. *J Am Heart Assoc.* 2020; 9: e013039.
- 483 12. Mayer AE, Löffler MC, Loza Valdés AE, Schmitz W, El-Merahbi R, Viera JT, et al. The kinase  
484 PKD3 provides negative feedback on cholesterol and triglyceride synthesis by suppressing insulin  
485 signaling. *Sci Signal.* 2019; 12.
- 486 13. Fraulob JC, Ogg-Diamantino R, Fernandes-Santos C, Aguila MB, Mandarim-de-Lacerda CA.  
487 A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas  
488 disease (NAFPD) in C57BL/6 mice fed a high fat diet. *J Clin Biochem Nutr.* 2010; 46: 212-23.
- 489 14. Avtanski D, Pavlov VA, Tracey KJ, Poretsky L. Characterization of inflammation and insulin  
490 resistance in high-fat diet-induced male C57BL/6J mouse model of obesity. *Animal Model Exp Med.*  
491 2019; 2: 252-8.
- 492 15. Selvin E, Rawlings AM, Bergenstal RM, Coresh J, Brancati FL. No racial differences in the  
493 association of glycated hemoglobin with kidney disease and cardiovascular outcomes. *Diabetes Care.*  
494 2013; 36: 2995-3001.
- 495 16. Selvin E. Are there clinical implications of racial differences in HbA1c? A difference, to be a  
496 difference, must make a difference. *Diabetes Care.* 2016; 39: 1462-7.

- 497 17. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Diet-induced type 2 diabetes  
498 in C57BL/6J mice. *Diabetes*. 1988; 37: 1163-7.
- 499 18. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of  
500 glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from  
501 the Whitehall II study. *Lancet*. 2009; 373: 2215-21.
- 502 19. Hulman A, Simmons RK, Brunner EJ, Witte DR, Færch K, Vistisen D, et al. Trajectories of  
503 glycaemia, insulin sensitivity and insulin secretion in South Asian and white individuals before  
504 diagnosis of type 2 diabetes: a longitudinal analysis from the Whitehall II cohort study. *Diabetologia*.  
505 2017; 60: 1252-60.
- 506 20. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for  
507 diabetes development. *Lancet*. 2012; 379: 2279-90.
- 508 21. Kim M, Song K, Kim YS. Alantolactone improves prolonged exposure of interleukin-6-  
509 induced skeletal muscle inflammation associated glucose intolerance and insulin resistance. *Front*  
510 *Pharmacol*. 2017; 8: 405.
- 511 22. Zou C, Wang Y, Shen Z. 2-NBDG as a fluorescent indicator for direct glucose uptake  
512 measurement. *J Biochem Biophys Methods*. 2005; 64: 207-15.
- 513 23. Asakawa H, Tokunaga K, Kawakami F. Relationship of leptin level with metabolic disorders  
514 and hypertension in Japanese type 2 diabetes mellitus patients. *J Diabetes Complications*. 2001; 15: 57-  
515 62.
- 516 24. Uslu S, Kebapçı N, Kara M, Bal C. Relationship between adipocytokines and cardiovascular  
517 risk factors in patients with type 2 diabetes mellitus. *Exp Ther Med*. 2012; 4: 113-20.
- 518 25. Abdella NA, Mojiminiyi OA, Moussa MA, Zaki M, Al Mohammedi H, Al Ozairi ES, et al.  
519 Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk  
520 factors and insulin resistance. *Diabet Med*. 2005; 22: 278-85.
- 521 26. López-Jaramillo P, Gómez-Arbeláez D, López-López J, López-López C, Martínez-Ortega J,  
522 Gómez-Rodríguez A, et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes.  
523 *Horm Mol Biol Clin Investig*. 2014; 18: 37-45.
- 524 27. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, et al. Mitochondrial  
525 dysfunction in the elderly: possible role in insulin resistance. *Science*. 2003; 300: 1140-2.
- 526 28. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal  
527 muscle in type 2 diabetes. *Diabetes*. 2002; 51: 2944-50.
- 528 29. Coughlan KA, Valentine RJ, Ruderman NB, Saha AK. AMPK activation: a therapeutic target  
529 for type 2 diabetes? *Diabetes Metab Syndr Obes*. 2014; 7: 241-53.
- 530 30. Hu Y, Chen Y, Ding L, He X, Takahashi Y, Gao Y, et al. Pathogenic role of diabetes-induced  
531 PPAR- $\alpha$  down-regulation in microvascular dysfunction. *Proc Natl Acad Sci U S A*. 2013; 110: 15401-  
532 6.

- 533 31. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1 $\alpha$ -  
534 responsive genes involved in oxidative phosphorylation are coordinately downregulated in human  
535 diabetes. *Nat Genet.* 2003; 34: 267-73.
- 536 32. Alonzo CA, Karaliota S, Pouli D, Liu Z, Karalis KP, Georgakoudi I. Two-photon excited  
537 fluorescence of intrinsic fluorophores enables label-free assessment of adipose tissue function. *Sci Rep.*  
538 2016; 6: 31012.
- 539